BioMarin Pharmaceutical Inc. (BVMF:B1MR34)

Brazil flag Brazil · Delayed Price · Currency is BRL
141.83
-3.21 (-2.21%)
At close: Dec 3, 2025
-25.95%
Market Cap 55.53B
Revenue (ttm) 16.49B
Net Income (ttm) 2.77B
Shares Out n/a
EPS (ttm) 14.29
PE Ratio 20.02
Forward PE 11.15
Dividend n/a
Ex-Dividend Date n/a
Volume 40
Average Volume 250
Open 141.83
Previous Close 145.04
Day's Range 141.83 - 141.83
52-Week Range 139.16 - 208.72
Beta 0.30
RSI 44.18
Earnings Date Feb 20, 2026

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NA... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 3,040
Stock Exchange Brazil Stock Exchange
Ticker Symbol B1MR34
Full Company Profile

Financial Performance

In 2024, BioMarin Pharmaceutical's revenue was $2.85 billion, an increase of 17.97% compared to the previous year's $2.42 billion. Earnings were $426.86 million, an increase of 154.62%.

Financial numbers in USD Financial Statements

News

There is no news available yet.